WO2019004590A1 - 박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용, 피부장벽 강화용, 및 항노화 또는 항염 조성물 - Google Patents

박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용, 피부장벽 강화용, 및 항노화 또는 항염 조성물 Download PDF

Info

Publication number
WO2019004590A1
WO2019004590A1 PCT/KR2018/005418 KR2018005418W WO2019004590A1 WO 2019004590 A1 WO2019004590 A1 WO 2019004590A1 KR 2018005418 W KR2018005418 W KR 2018005418W WO 2019004590 A1 WO2019004590 A1 WO 2019004590A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
extract
skin
fine dust
mint
Prior art date
Application number
PCT/KR2018/005418
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
김형준
김미진
이태룡
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170083668A external-priority patent/KR102212625B1/ko
Priority claimed from KR1020170083707A external-priority patent/KR102212626B1/ko
Priority claimed from KR1020170083726A external-priority patent/KR102212627B1/ko
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to SG11201912760RA priority Critical patent/SG11201912760RA/en
Priority to JP2019572193A priority patent/JP7158426B2/ja
Priority to CN201880056941.3A priority patent/CN111655225A/zh
Publication of WO2019004590A1 publication Critical patent/WO2019004590A1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • compositions for treating skin cell damage caused by fine dusts More specifically, as compared to the steady-state skin cells, thereby significantly change and the like of the skin cells biomarker gene expression level is changed by the fine dust to care the skin cell damage, peppermint second (Mentha Arvensis < / RTI > extract.
  • Skin is a part of the body that is directly exposed to the external environment. It acts as a protective layer to protect important organs of our body, as well as controlling water evaporation and protecting the body from external infections.
  • skin that prevents virus penetration from the outside if exposed to excessive ultraviolet rays or pollutants, causes skin irritation, and especially, it is injured by yellow dust accompanied by strong wind and dirt.
  • Dust is a phenomenon in which small sand or loess is floated in the inland deserts of China and Mongolia, and is transported far away in the upper winds, falling near the ground. In Korea, yellow dust occurs periodically every spring. Dusts are a complex of organic matter and inorganic matter, and their physical characteristics and constituents are very diverse depending on when and where they occur, and they also contain metal components that can biologically affect them. Large dust-like particles, such as dusts, usually stay in the source or periphery, dust particles of small particle size are introduced into the domestic area, and when such dust is inhaled, the dust collects in the gas- Of the patients. In addition, skin cell damage has been observed to increase in skin of people residing in dusty, dusty areas.
  • the epidermis plays an important role in preventing water evaporation inside the human body.
  • the epidermis is divided into stratum corneum, granular layer, superficial layer, and basal layer in order from the outside.
  • Cells of stratum corneum act like bricks, and interstitial lipids between keratinocytes act like mortar to form skin barrier.
  • a healthy human keratinocyte has a high concentration of natural moisturizing factor (NMF) to help maintain moisture in the skin.
  • NMF natural moisturizing factor
  • substances such as amino acids are water-soluble, Thereby suppressing drying.
  • IL-36G is a useful biomarker in psoriasis caused by skin barrier weakness (see Non-Patent Document 1). It is also known that S100A7 is an index related to atopic dermatitis and psoriasis due to impairment of skin barrier function (see Non-Patent Document 2). It is also known that LCE3D is an index related to the psoriasis risk gene (see Non-Patent Document 3).
  • interleukin-1 is classified as a senescence-associated secretory phenotype (SASP), and interleukins 1a and 1b (IL-1a and IL-1b) are representative aging markers and exhibit cell senescence (See Non-Patent Document 4).
  • SASP senescence-associated secretory phenotype
  • IL-1a and IL-1b interleukins 1a and 1b
  • XDH is indicative of oxidative stress induced by prolonged exposure to stimulus sources and, consequently, is indicative of exogenous skin aging Patent Document 5).
  • PTGS2 COX-2
  • IL-1a is increased in skin cells exposed to stimulus source in relation to skin inflammation (see Non-Patent Document 6).
  • XDH xanthine dehydrogenase
  • Non-Patent Document 2 Son et al, " S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL-6 secretion through IJB / NF-JB signaling ", Experimental Dermatology, John Wiley & Sons A /
  • Non-Patent Document 3 Bergboer et al, " Psoriasis Risk Genes of the Late Corned Envelope-3 Group Are Distinctly Expressed Compared with Genes of Other LCE Groups ", The American Journal of Pathology, Vol. 178, No. 4, April 2011.
  • Non-Patent Document 4 Jean-Philippe Coppe, et al, "The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression", Annual Review of Pathology: Mechanisms of Disease, volume 5, 2010.
  • Non-Patent Document 5 Kim, HJ, et al., "Transcriptome analysis of airborne PM 2.5 -induced detrimental effects on human keratinocytes", Toxicology Letters 273, 26-35,
  • Non-Patent Document 6 Natalia D Magnani, et al., "Skin Damage Mechanisms Related to Airborne Particulate Matter Exposure", toxicological sciences, 149 (1), 2016, 227-236.
  • the present inventors have found that fine dusts adversely affect the skin, and by such an influence, they also affect the expression of skin cell genes, thereby causing symptoms such as skin cell damage.
  • the present invention provides a composition for care of damage of skin cells caused by fine dust particles.
  • the present invention provides a composition for external application for skin comprising an extract of peppermint powder as an active ingredient, comprising IL-1a (NM_000575), a gene in a skin cell to which an expression amount is affected by fine dust, , Which regulate at least one expression level selected from the group consisting of IL-1B (NM_000576), IL-36G (NM_019618), S100A7 (NM_002963), LCE3D (NM_032563), PTGS2 (NM_000963), XDH
  • IL-1B IL-1B
  • IL-36G a gene in a skin cell to which an expression amount is affected by fine dust
  • S100A7 NM_002963
  • LCE3D NM_032563
  • PTGS2 NM_000963
  • XDH XDH
  • the amount of gene expression changed by the fine dust can be returned to a normal level and skin cell damage can be cared.
  • the amount of gene expression, which is changed by inflammation or aging stimulation can be returned to a normal level and skin cell damage can be reduced.
  • composition for skin barrier enhancement provided by the present invention, it is possible to reduce the damage of skin cells by returning the amount of gene expression, which is changed by a stimulus source causing skin barrier weakness, to a normal level.
  • FIG. 1 shows the cell survival rate by treatment with a fine dust extract, wherein ADSP represents Asian dust-storm particles, and PM10 (Particulate matter 10) represents fine dust particles having a particle size of 10 ⁇ m And PM2.5 (Particulate matter 2.5) represents fine dust having a particle size of 2.5 mu m.
  • FIG. 2A shows that mRNA expression of the S100A7 gene is increased in PM2.5 fine dust-stimulated skin cells.
  • FIG. 2B shows that mRNA expression of the IL-1A gene is increased in PM2.5 fine dust-stimulated skin cells.
  • FIG. 2C shows that mRNA expression of IL-1B gene is increased in PM2.5 fine dust-stimulated skin cells.
  • FIG. 2d shows that mRNA expression of IL-36G gene is increased in skin cells stimulated by PM2.5 fine particles.
  • FIG. 2E shows that the amount of mRNA expression of the PTGS2 gene is increased in PM2.5 fine dust-stimulated skin cells.
  • FIG. 2f shows that the amount of mRNA expression of the LCE3D gene is increased in the skin cells stimulated by PM2.5 fine particles.
  • FIG. 2g shows that the amount of mRNA expression of the XDH gene is increased in the skin cells stimulated by PM2.5 fine particles.
  • FIG. 3A shows that the expression level of the S100A7 gene changed in the skin cells stimulated by the fine dust was returned to a normal level by treatment with the extract of Mint.
  • FIG. 3B shows that the expression level of the IL-1A gene changed in the skin cells stimulated by the fine dust was returned to the normal level by treatment with the extract of Mint.
  • FIG. 3C shows that the expression level of IL-1B gene changed in skin cells stimulated by fine dust returns to a normal level by treatment with mint extract.
  • FIG. 3D shows that the expression level of IL-36G gene changed in skin cells stimulated by fine dust returns to a normal level by treatment with mint extract.
  • FIG. 3E shows that the expression level of PTGS2 gene changed in the skin cells stimulated by the fine dust was returned to the normal level by treatment with the extract of Mint.
  • FIG. 3f shows that the expression level of the LCE3D gene changed in the skin cells stimulated by the fine dust is returned to the normal level by the treatment of the extract of the mint extract.
  • FIG. 3g shows that the expression amount of the XDH gene changed in the skin cells stimulated by the fine dust was returned to the normal level by the treatment with the extract of mint extract.
  • Mentha Arvensis is a perennial herbaceous perennial plant belonging to the monocotyledonous plant of the monocotyledonous plant.
  • the peppermint is characterized by a refreshing and refreshing flavor, and its leaves and stems grow in a cool climate. It mainly contains a menthol ingredient and emits a unique flavor. It also contains nutritional ingredients such as vitamins.
  • the composition comprises a mint extract.
  • leaf or stem of peppermint can be used, but is not limited thereto.
  • the microbial added peppermint can be specifically fermented at 22-30 ° C for 24-72 hours. In one embodiment, the extract is fermented at 26 DEG C for about 48 hours.
  • the mint extract may be extracted with a particular extraction solvent to form a mint extract.
  • the mint extract may be prepared by extracting leaves or stems of mint leaves with water or an organic solvent.
  • the leaves or stems of peppermint are selected from the group consisting of water, C 1 -C 6 anhydrous or lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane May be prepared by extraction with one or more extraction solvents.
  • the mint extract may be extracted at room temperature.
  • the mint extract may be obtained by extracting with the extraction solvent, followed by addition of one or more of filtration, concentration, separation or drying.
  • the mint extract may be subjected to one or more filtration steps, and in one embodiment, it is subjected to two filtration steps.
  • the separation process may include a centrifugation process.
  • the extraction can be carried out in the presence of water, a C 1 -C 6 anhydrous or a lower alcohol, a polar solvent comprising acetone and butylene glycol, and a polar solvent including ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane And a low polarity solvent may be used as a solvent.
  • the solvent may be 50-90% ethanol aqueous solution, and may be 60-80% ethanol or 65-75% ethanol aqueous solution.
  • the solvent may be about 70% aqueous ethanol solution.
  • the extract may be concentrated under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction.
  • the extract of peppermint powder according to the present invention can be extracted by a conventional method in the art, and is not limited by the above-mentioned method.
  • the composition may comprise from 0.000001 to 30% by weight of peppermint root extract, based on the total weight of the composition.
  • the content thereof is 0.000001 to 30% by weight, the skin care effect by fine dust caused by the mint extract is excellent.
  • 0.0000001 wt% or more 0.0000005 wt% or more, 0.0000007 wt% or more, 0.0000009 wt% or more, 0.0000009 wt% or more, 0.000001 wt% or more, 0.000002 wt% or more, 0.000004 wt% or more, 0.000006 wt% or more, 0.000008 wt.
  • % 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, or 0.00000009 wt% or less.
  • Another aspect of the present invention includes skin care care applications for fine dusts of the composition.
  • a method for skin care damage caused by fine dust of the object in another aspect of the invention the method peppermint second (Mentha Comprising administering an effective amount of an Arvensis extract to a subject in need thereof.
  • Peppermint seconds in the manufacture of a composition for the skin damage caused by fine dust care in another aspect of the present invention extracts.
  • Another aspect of the present invention provides Mentha Arvensis extract for skin damage care by fine dust.
  • fine dust refers to a particulate matter that is a very small material that is invisible to the naked eye and that floats or drifts in the air for a long time. Particularly, particulate matter having a particle size of 2.5 ⁇ m or less is called “ultrafine dust”. In the present invention, “fine dust” is also intended to include “ultrafine dust”.
  • care refers to effective prevention of skin cells from stimulation and inhibition, prevention, or recovery (restoration) of changes in the expression level of a specific gene by stimulation.
  • the present invention provides a composition for inhibiting damage of skin cells caused by fine dusts by controlling the expression level of a specific gene in skin cells damaged by fine dust to a normal level.
  • the genes in the skin cells to which the expression amount is affected by the fine dust include IL-1 ⁇ (NM_000575), IL-1B (NM_000576), IL-36G (NM_019618), S100A7 (NM_002963), LCE3D ), PTGS2 (NM_000963), XDH (NM_000379), and the like.
  • IL-1B (NM_000575), IL-36G (NM_019618), S100A7 (NM_002963), LCE3D (NM_032563), PTGS2 (NM_000963) and XDH (NM_000379) Since it is a gene, the amount of expression of these genes is suppressed and regulated to a normal level, thereby suppressing damage of skin cells.
  • Analysis of the expression level of the gene or protein can be performed using a microarray, PCR, NGS (Nest Generation Sequencing), Western blot, northern blot, ELISA, radioimmunoassay, radioimmunoassay, tissue immuno staining, Can be analyzed using a variety of analytical methods known in the art.
  • Damage to the skin cells is caused by fine dust, which leads to inflammation and further damage to the skin cells.
  • the skin condition can be improved by taking care of the vicious cycle of the skin cell damage by the peppermint extract.
  • Another aspect of the present invention includes anti-aging and anti-inflammatory uses of the composition of the present invention.
  • a method for anti-aging a subject comprising administering an effective amount of a Mentha Arvensis extract to a subject in need thereof.
  • Another aspect of the present invention provides the use of Mentha Arvensis extract in preparing a composition for antiaging .
  • Peppermint for anti-aging in a further aspect of the invention second (Mentha Arvensis < / RTI > extract.
  • a method for anti-inflammation of a subject comprising administering an effective amount of a Mentha Arvensis extract to a subject in need thereof.
  • Another aspect of the present invention provides the use of Mentha Arvensis extract in preparing a composition for anti-inflammation.
  • Peppermint seconds for the anti-inflammatory properties in a further aspect of the present invention (Mentha Arvensis < / RTI > extract.
  • the present invention provides a composition for inhibiting inflammation or aging by modulating the expression level of a specific gene in a skin cell damaged by inflammation or aging stimulation to a normal level.
  • IL-1a NM_000575
  • IL-1B NM_000576
  • PTGS2 NM_000963
  • XDH NM_000379
  • the expression levels of IL-1a NM_000575
  • IL-1B NM_000576
  • PTGS2 NM_000963
  • XDH NM_000379
  • genes whose expression levels are increased by inflammation or aging stimulation used in the present invention are shown in Table 2.
  • Name means the genebank accession ID of NCBI
  • Gene Symbol means the official gene symbol
  • Gene title means the name of each gene.
  • Another aspect of the invention includes the use of the composition of the present invention to enhance skin barrier.
  • the present invention provides a composition for enhancing skin barrier by regulating the expression level of a specific gene in skin cells damaged by a stimulus causing skin barrier weakness to a normal level.
  • the genes in the skin cells to which the expression level is influenced by the stimuli that cause skin barrier weakness include S100A7 (NM_002963), IL-36G (NM_019618), and LCE3D (NM_032563). Since the expression levels of S100A7 (NM_002963), IL-36G (NM_019618) and LCE3D (NM_032563) are increased by stimulation that causes skin barrier weakness, the expression level of these genes is suppressed and regulated to a normal level .
  • the genes whose expression levels are increased by the stimuli causing skin barrier weakness used in the present invention are shown in [Table 3].
  • Name means the genebank accession ID of NCBI
  • Gene Symbol means the official gene symbol
  • Gene title means the name of each gene.
  • a method for reinforcing skin barrier of the subject in another aspect of the invention, the method peppermint second (Mentha Comprising administering an effective amount of an Arvensis extract to a subject in need thereof.
  • Peppermint seconds in the manufacture of a composition for strengthening the skin barrier in a further aspect of the present invention (Mentha Arvensis ) extracts.
  • Mint seconds to strengthen the skin barrier in another aspect of the present invention (Mentha Arvensis < / RTI > extract.
  • the composition may be a cosmetic composition, a pharmaceutical composition, or a health functional food composition.
  • cosmetic composition examples include cosmetics such as various creams, lotion creams, lotions, skins, and the like, and cleansing, cleansing agents, soaps, and essences.
  • the cosmetic composition to which the composition containing the mint extract of the present invention is added may take the form of a solution, an emulsion, a viscous mixture or the like.
  • the cosmetic of the present invention is not particularly limited in its formulation, and examples thereof include an emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, Formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, rinse, body cleanser, soap, hair dye, spray and the like.
  • the ingredients other than the mint extract may be mixed and selected without difficulty by those skilled in the art depending on the formulations of the other cosmetics or the purpose of use.
  • the cosmetic of the present invention may comprise a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.
  • the cosmetic composition of the present invention may contain, in addition to the above essential ingredients, other ingredients usually added to cosmetics, if necessary.
  • Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.
  • organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.
  • the components to be added in addition to these components are not limited thereto, and any of the above components can be compounded within a range that does not impair the objects and effects of the present invention.
  • compositions comprising the peppermint extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
  • the pharmaceutical composition containing the mint extract may be formulated into tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays according to a conventional method, And can be formulated and used in any form suitable for pharmaceutical preparations.
  • the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of various relevant factors such as the severity of the symptoms, the route of administration selected, the age, sex, weight and health status of the subject.
  • the dosage of the active ingredient may be from 0.0001 mg / kg / day to 3000 mg / kg / day, for example from 10 mg / kg / day to 500 mg / kg / day.
  • the health food is produced by using a raw material or a component (functional raw material) having a function useful for a nutrient or a human body which is likely to be deficient in a daily meal, Or to maintain or improve health through the activation of physiological functions.
  • a raw material or a component having a function useful for a nutrient or a human body which is likely to be deficient in a daily meal, Or to maintain or improve health through the activation of physiological functions.
  • the present invention is not limited thereto.
  • the health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and circles, but is not limited thereto and may be manufactured and processed in any form according to the law.
  • the health beverage composition has no particular limitation on the other ingredients other than the above-mentioned compounds as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary beverages.
  • natural carbohydrates are conventional sugars such as monosaccharide polysaccharides, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • Natural flavors tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings other than those described above.
  • the actual dosage of the active ingredient administered by the health functional food composition should be determined in light of various relevant factors such as the severity of the symptoms, the selected route of administration, the age, sex, weight and health status of the subject .
  • the dosage of the active ingredient may be from 0.0001 mg / kg / day to 1000 mg / kg / day, for example from 0.02 mg / kg / day to 6 mg / kg / day.
  • Mint leaf and Acetobacter aceti were prepared, and they were fermented at 26 DEG C for 48 hours. Then, the fermented product was extracted with an extraction solvent obtained by mixing purified water and ethanol at a ratio of 3: 7, that is, 70% ethanol as an extraction solvent at room temperature. After extracting at room temperature, primary filtration was performed to remove the solid material contained in the extract. Then, the extract was concentrated to remove ethanol, and then it was separated and purified. After centrifugation, secondary filtration and drying, the extracts were obtained.
  • the filter pack was used for about 24 hours by replacing the filter and denuder at around 10:00 am on each measurement day.
  • the filter pack and the denuder were replaced by a low volume air sampler (Sensidyne, Gillian, Low Volume Air Sampler, FL, USA) Respectively.
  • fine dust was collected daily from the windy area of Seoul (Gyeonggi-do, Korea), and the measurement time was measured by turning on the timer while turning on the vacuum pump and turning off the timer Time was recorded.
  • the flow rate was measured with a flow meter (Model 4143, TSI Inc.) at the start of the measurement at a flow rate of 16.7 L / min, and the flow rate was measured again at the end of the measurement.
  • the Teflon filter in the filter pack weighed before and after sampling.
  • the sample was weighed into a desiccator (NIKKO, Japan) with a relative humidity of 40% for 24 hours and then weighed twice on an electronic balance (DVG215CD, Ohaus) .
  • DVG215CD, Ohaus an electronic balance
  • the extraction of fine dust was carried out by wetting the Teflon filter with 1 mL of ethanol, placing the filter with 14 mL of DW, closing the lid with the filter surface of the filter touching the water surface, and ultrasonically applying the filter with the ultrasonic cleaner for 30 minutes.
  • the water content of the filter was completely removed for 48 hours in a decicator, and then the weight of the filter was measured using a super-precision scale system (Mettler Toledo Company) Weighed and weighed before and after filter extraction.
  • Human normal epidermal keratinocytes were purchased from Lonza, Inc. (Walkersville, Maryland, USA), subcultured and cultured in a CO 2 incubator at 37 ° C under 5% CO 2 Lt; / RTI > The cell culture was in accordance with Lonza's guidelines.
  • KGM-2 Bullet kit, CC-4152 (ingredient: BPE (bovine pituitary extract)), human epidermal growths (KBM- (Gentamycin Suflate + Amphofericin-B: GA), human epidermal growth factor (hEGF), insulin, Hydrocortisone, Transferrin, Epinephrine and gentamycin sulfate (KGM-2 Bullet Kit, CC-3107) was added to the reaction mixture.
  • Example 4 (normal human) Treatment of fine dust and cytotoxicity measurement on keratinocyte cell line
  • MTT experiments were carried out using keratinocyte lines (normal human) by the method of Mossman et al. (J. Immunol. Methods, 65, 55-63, 1983) in order to confirm cytotoxicity through fine dusting.
  • a fine dust having a diameter of 2.5 ⁇ ⁇ obtained by using the 24-well plate and obtained in Example 2 was dispersed in purified water to prepare a fine dust dispersion.
  • 2.5 ⁇ ⁇ 10 5 Cells cultured under the conditions of the number of well cells were treated with the fine dust dispersion and cultured for 24 hours.
  • the medium was then removed and the formazan crystal formed was dissolved in 500 ⁇ ⁇ of DMSO.
  • the lysate was transferred to a 96-well plate and aliquoted and the OD value measured at 540 nm absorbance. The measurement results are shown in Fig.
  • the concentration (IC20) showing an 80% survival rate with respect to cytotoxicity by a dispersion in which fine particles of 2.5 micrometer or less were dispersed in the cell line was 12.5 g / Ml.
  • RNA-base sequence data processing and analysis reference was made to the general analysis step developed by Trapnell et al. (2012).
  • alignment was performed using Tophat (Trapnell et al., 2009) and human genome (hg19), and the amount of data for each sample was confirmed using EVER-seq renamed RSeQC (Wang et al., 2012 ).
  • transcripts were quantified using Cufflinks, and transcription levels were compared between the fine dust dispersion treated and normal samples (Trapnell et al., 2010).
  • a stringent cutoff of ⁇ 2.0 fold-change was applied to the FDR adjusted p-value ⁇ 0.05 to determine the gene that showed significant expression differences in the treatment of the dispersion of fine dust with a diameter of 2.5 ⁇ m.
  • the measurement results are shown in the following [Table 4] and [ Figure 2a] to [ Figure 2g].
  • Human microkeratin skin cells cultured in Example 3 in the amount of fine particles having a diameter of 2.5 ⁇ ⁇ extracted in Example 2 were treated in an amount of 12.5 ⁇ ⁇ in 1 ml of the cell culture medium and applied to the applied biosystems TaqMan® Primers) to determine the relative mRNA expression levels.
  • the extract prepared in Example 1 was used.
  • RT-PCR was performed using the primers shown in Table 5 -RT-PCR: real-time reverse transcription polymerase chain reaction).
  • the gene expression patterns of the cells were evaluated by real-time PCR using a TaqMan gene expression assay kit (Applied Biosystems, Foster City, Calif.) Of Applied Biosystems. Respectively.
  • Both Q-RT-PCR and real-time PCR were performed according to the standard protocols distributed by Life Technologies. Specifically, the Q-RT-PCR was performed at 95 ° C for 20 seconds, followed by 95 ° C for 3 seconds and 60 ° C for 30 seconds For 40 cycles.
  • FIGS. 3A to 3G there is a gene whose expression level is increased or decreased in skin cells stimulated by fine dust, and the expression of interleukin-1 alpha (IL-1a) Interleukin 1 Beta (IL-1B), Interleukin 36 Gamma (IL-36G), S100 Calcium Binding Protein A7 (S100A7), Latex Keratinocyte 3D (LCE3D), Prostaglandin-Endo Peroxide Synthase 2 (PTGS2) And the amount of dehydrogenase (XDH) gene expression was decreased.
  • IL-1a Interleukin-1 alpha
  • IL-1B Interleukin 1 Beta
  • IL-36G Interleukin 36 Gamma
  • S100A7 S100 Calcium Binding Protein A7
  • LCE3D Latex Keratinocyte 3D
  • PTGS2 Prostaglandin-Endo Peroxide Synthase 2
  • XDH dehydrogenase
  • FIGS. 3A to 3G there is a gene whose expression level is increased in skin cells stimulated by inflammation or aging stimulation, and the expression of interleukin 1 alpha (IL-1a ), Interleukin 1 beta (IL-1B), prostaglandin-endo peroxidase 2 (PTGS2) and xanthine dehydrogenase (XDH) gene.
  • IL-1a interleukin 1 alpha
  • IL-1B Interleukin 1 beta
  • PTGS2 prostaglandin-endo peroxidase 2
  • XDH xanthine dehydrogenase
  • the extract of mint is effective for protecting skin cells from skin cell damage due to irritation or aging stimulation, and inhibiting or preventing the change in the expression amount of the specific gene described above by inflammation or aging stimulation, As shown in FIG.
  • FIGS. 3A to 3G there is a gene whose expression level is increased in skin cells stimulated by a stimulus causing weakening of the skin barrier, and the expression of interleukin 36 gamma (IL) -36G), S100 calcium-binding protein A7 (S100A7), and late keratin hyaluronan 3D (LCE3D) gene.
  • IL interleukin 36 gamma
  • S100A7 S100 calcium-binding protein A7
  • LCE3D late keratin hyaluronan 3D
  • the extract of peppermint larvae effectively protects skin cells from stimulation by fine dusts, and inhibits or prevents the change in the expression level of the above-mentioned specific gene by the stimulation, .
  • the cosmetic composition, the pharmaceutical composition and the health functional food composition can be applied to various formulations, and the present invention is not limited thereto .
  • the tablets were prepared by mixing 100 mg of mint extract, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate according to the examples of the present invention, followed by tableting according to a conventional preparation method of tablets.
  • Mint extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2
  • 100 mg of mint extract, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate according to the present invention were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.
  • Mint extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2
  • mint extract 50 mg of mint extract, 250 mg of anhydrous crystalline glucose and 550 mg of starch according to the present invention were mixed and granulated into granules using a fluidized bed granulator and filled in a capsule.
  • Mint extract 50 Anhydrous crystalline glucose 250 Starch 550
  • Mint extract 5.00 maintain Suitable amount Sodium hydroxide Suitable amount Sodium chloride Suitable amount Spices Suitable amount Purified water Balance
  • Mint extract 3.00 Polyethylene glycol monostearate 2.00 Self emulsifying monostearic acid glycerin 5.00 Cetyl alcohol 4.00 Squalene 6.00 Tri-2-ethylhexanoic acid glyceryl 6.00 Sphingoglycolipids 1.00 1,3-butylene glycol 7.00 Purified water Balance
  • Vitamin A acetate 70 ⁇ g Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 ⁇ g Vitamin C 10 mg Biotin 10 ⁇ g Nicotinic acid amide 1.7 mg Folic acid 50 ⁇ g Calcium pantothenate 0.5 mg Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium monophosphate 15 mg Dicalcium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/KR2018/005418 2017-06-30 2018-05-11 박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용, 피부장벽 강화용, 및 항노화 또는 항염 조성물 WO2019004590A1 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SG11201912760RA SG11201912760RA (en) 2017-06-30 2018-05-11 Composition for treating skin cell damage caused by fine dust, for strengthening skin barrier, and for anti-aging or anti-inflammation, containing mentha arvensis extract
JP2019572193A JP7158426B2 (ja) 2017-06-30 2018-05-11 メンタアルベンシス抽出物を含む微塵による皮膚細胞損傷ケア用、皮膚バリア強化用、及び抗老化又は抗炎症組成物
CN201880056941.3A CN111655225A (zh) 2017-06-30 2018-05-11 用于治疗微尘造成的皮肤细胞损伤、增强皮肤障壁、及抗老化或抗发炎的包含野薄荷提取物的组合物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2017-0083726 2017-06-30
KR10-2017-0083668 2017-06-30
KR10-2017-0083707 2017-06-30
KR1020170083668A KR102212625B1 (ko) 2017-06-30 2017-06-30 박하초 추출물을 포함하는 항노화 또는 항염 조성물
KR1020170083707A KR102212626B1 (ko) 2017-06-30 2017-06-30 박하초 추출물을 포함하는 피부장벽 강화용 조성물
KR1020170083726A KR102212627B1 (ko) 2017-06-30 2017-06-30 박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물

Publications (1)

Publication Number Publication Date
WO2019004590A1 true WO2019004590A1 (ko) 2019-01-03

Family

ID=64742943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005418 WO2019004590A1 (ko) 2017-06-30 2018-05-11 박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용, 피부장벽 강화용, 및 항노화 또는 항염 조성물

Country Status (5)

Country Link
JP (1) JP7158426B2 (zh)
CN (1) CN111655225A (zh)
SG (1) SG11201912760RA (zh)
TW (1) TWI798219B (zh)
WO (1) WO2019004590A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155395A1 (en) * 2007-12-13 2009-06-18 Sagittarius Life Science Corp. SF303T, Anti-Inflammatory and Anti-Acne Agent
KR20140052576A (ko) * 2012-10-25 2014-05-07 코웨이 주식회사 식물 발효 추출물을 포함하는 프리바이오틱 화장료 조성물
KR20150122983A (ko) * 2014-04-24 2015-11-03 (주)아모레퍼시픽 박하초를 함유하는 화장료 조성물
KR20160053557A (ko) * 2014-11-05 2016-05-13 최철원 한약재를 이용한 피부질환 개선용 조성물 및 그 제조방법
KR20160109355A (ko) * 2015-03-11 2016-09-21 (주)시크릿허브코리아 천연 생약초 추출물을 포함하는 피부 노화, 여드름 개선 및 피부 미백용 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000212028A (ja) 1999-01-27 2000-08-02 Pola Chem Ind Inc ストレス障害対応皮膚外用剤
JP2008031111A (ja) 2006-07-31 2008-02-14 Noevir Co Ltd アルギナーゼ活性促進剤
JP2011148742A (ja) 2010-01-22 2011-08-04 Noevir Co Ltd 細胞賦活剤及び皮膚外用剤
JP2012188399A (ja) 2011-03-11 2012-10-04 Kao Corp 皮膚保湿剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155395A1 (en) * 2007-12-13 2009-06-18 Sagittarius Life Science Corp. SF303T, Anti-Inflammatory and Anti-Acne Agent
KR20140052576A (ko) * 2012-10-25 2014-05-07 코웨이 주식회사 식물 발효 추출물을 포함하는 프리바이오틱 화장료 조성물
KR20150122983A (ko) * 2014-04-24 2015-11-03 (주)아모레퍼시픽 박하초를 함유하는 화장료 조성물
KR20160053557A (ko) * 2014-11-05 2016-05-13 최철원 한약재를 이용한 피부질환 개선용 조성물 및 그 제조방법
KR20160109355A (ko) * 2015-03-11 2016-09-21 (주)시크릿허브코리아 천연 생약초 추출물을 포함하는 피부 노화, 여드름 개선 및 피부 미백용 조성물 및 이의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BISWAS, N. N.: "Antioxidant, antimicrobial, cytotoxic and analgesic activities of ethanolic extract of Mentha arvensis L.", ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE, vol. 4, no. 10, 2014, pages 792 - 797, XP055679271, DOI: 10.12980/APJTB.4.2014C1298 *

Also Published As

Publication number Publication date
SG11201912760RA (en) 2020-01-30
TWI798219B (zh) 2023-04-11
CN111655225A (zh) 2020-09-11
JP7158426B2 (ja) 2022-10-21
JP2020525491A (ja) 2020-08-27
TW201904551A (zh) 2019-02-01

Similar Documents

Publication Publication Date Title
WO2019103329A1 (ko) 갈색거저리 발효 추출물을 유효성분으로 포함하는 항산화용 조성물
WO2019088421A1 (ko) 녹차 유래 유산균을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
WO2017061769A1 (ko) 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 탈모방지 또는 발모촉진용 조성물
WO2020111674A1 (ko) 녹차 유래 유산균을 포함하는 미세먼지에 의한 탈모 케어용 조성물
KR102164345B1 (ko) 발효차 추출물을 포함하는 피부장벽 강화용 조성물
WO2019059527A1 (ko) 매화꽃 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
WO2019078463A1 (ko) 녹차 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
WO2019004590A1 (ko) 박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용, 피부장벽 강화용, 및 항노화 또는 항염 조성물
WO2019103486A2 (ko) 차나무 뿌리 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용, 피부장벽 강화용, 항노화 및 항염 조성물
KR102212626B1 (ko) 박하초 추출물을 포함하는 피부장벽 강화용 조성물
WO2019066261A1 (ko) 발효차 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용, 피부장벽 강화용, 및 항산화, 항노화 또는 항염 조성물
KR102164346B1 (ko) 발효차 추출물을 포함하는 항산화, 항노화 또는 항염 조성물
KR102212627B1 (ko) 박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
WO2016163698A1 (ko) 미세먼지에 의한 피부 손상 진단용 조성물 및 갈랑긴을 유효성분으로 포함하는 조성물
KR20190037881A (ko) 무궁화 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
KR102429852B1 (ko) 차나무 뿌리 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
KR102152753B1 (ko) 발효차 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
KR102212625B1 (ko) 박하초 추출물을 포함하는 항노화 또는 항염 조성물
WO2019066252A2 (ko) 무궁화 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 또는 항균성 펩티드 저해용 조성물
KR102429851B1 (ko) 차나무 뿌리 추출물을 포함하는 항노화 또는 항염 조성물
KR102429850B1 (ko) 차나무 뿌리 추출물을 포함하는 피부장벽 강화용 조성물
KR102087189B1 (ko) 무궁화 추출물을 포함하는 항균성 펩티드 저해용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18824246

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019572193

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18824246

Country of ref document: EP

Kind code of ref document: A1